Press release
Investigation announced for Investors in shares of Verrica Pharmaceuticals Inc. (NASDAQ: VRCA)
An investigation for investors in Verrica Pharmaceuticals Inc. (NASDAQ: VRCA) shares over potential securities laws violations.
Investors who purchased shares of Verrica Pharmaceuticals Inc. (NASDAQ: VRCA), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Verrica Pharmaceuticals Inc. (NASDAQ: VRCA) concerning whether a series of statements by Verrica Pharmaceuticals Inc. regarding its business, its prospects and its operations were materially false and misleading at the time they were made.
West Chester, PA based Verrica Pharmaceuticals Inc., a dermatology therapeutics company, develops and commercializes treatments for people with skin diseases in the United States. On May 24, 2022, after the market closed, Verrica Pharmaceuticals Inc. announced that the U.S. Food and Drug Administration ("FDA") had issued a Complete Response Letter regarding its New Drug Application, VP-102. Specifically, the FDA cited "deficiencies identified at a general reinspection of Sterling Pharmaceuticals Services, LLC (Sterling), the contract manufacturing organization (CMO) that manufactures Verrica's bulk solution drug product."
Shares of Verrica Pharmaceuticals Inc. (NASDAQ: VRCA) declined from $9.22 per share on April 7, 2022, to as low as $1.77 per share on June 1, 2022.
Those who purchased shares of Verrica Pharmaceuticals Inc. (NASDAQ: VRCA) have certain options and should contact the Shareholders Foundation.
Contact:
Christopher Clausen
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Investigation announced for Investors in shares of Verrica Pharmaceuticals Inc. (NASDAQ: VRCA) here
News-ID: 2643129 • Views: …
More Releases from Shareholders Foundation
Lawsuit Alert: Investors who lost money with James Hardie Industries plc (NYSE: …
An investor, who purchased shares of James Hardie Industries plc (NYSE: JHX), filed a lawsuit over alleged violations of Federal Securities Laws by James Hardie Industries plc in connection with certain allegedly false and misleading statements.
Investors who purchased shares of James Hardie Industries plc (NYSE: JHX) have certain options and for certain investors are short and strict deadlines running. Deadline: December 23, 2025. NYSE: JHX investors should contact the Shareholders…
Investigation announced for Long-Term Investors in SelectQuote, Inc. (NYSE: SLQT …
An investigation on behalf of current long-term investors in shares of SelectQuote, Inc. (NYSE: SLQT) concerning potential breaches of fiduciary duties by certain directors and officers of SelectQuote, Inc. was announced.
Investors who are current long term investors in SelectQuote, Inc. (NYSE: SLQT) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term…
Lawsuit filed for Investors who lost money with shares of MoonLake Immunotherape …
An investor, who purchased shares of MoonLake Immunotherapeutics (NASDAQ: MLTX), filed a lawsuit over alleged violations of Federal Securities Laws by MoonLake Immunotherapeutics in connection with certain allegedly false and misleading statements.
Investors who purchased a significant amount of shares of MoonLake Immunotherapeutics (NASDAQ: MLTX) between March 10, 2024 and September 29, 2025, have certain options and for certain investors are short and strict deadlines running. Deadline: December 15, 2025. NASDAQ:…
Dow Inc. (NYSE: DOW) Investor Alert: Deadline in Lawsuit on October 28, 2025
A deadline is coming up on October 28, 2025 in the lawsuit filed for certain investors of Dow Inc. (NYSE: DOW) over alleged securities laws violations by Dow Inc.
Investors who purchased shares of Dow Inc. (NYSE: DOW) have certain options and there are strict and short deadlines running. Deadline: October 28, 2025. Dow Inc. (NYSE: DOW) stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 -…
More Releases for Verrica
Genital Warts Market Outlook Report | Verrica Pharmaceuticals, Novan Inc., G&E H …
DelveInsight's "Genital Warts Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Genital Warts, historical and forecasted epidemiology as well as the Genital Warts market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
The Genital Warts market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Genital Warts market size…
Verrica Pharmaceuticals "VP-102" Market size expansion of Several Folds by 2032
[Las Vegas, United States] DelveInsight, a leader in healthcare research firm, has recently published an in-depth report on VP-102 (Verrica Pharmaceuticals) providing insights into the drug market landscape and market forecast of VP-102 upto 2032. The report, titled "VP-102 Market Size, Forecast, and Emerging Insight - 2032" is now available for review and analysis.
Are you interested in finding out the projected market size of VP-102 in 2032? VP-102 Market…
Common Warts Market to Witness Growth by 2032 | Nielsen BioSciences, Veloce BioP …
DelveInsight's "Common Warts Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Common Warts, historical and forecasted epidemiology as well as the Common Warts market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
The Common Warts market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Common Warts market size…
Genital Warts Market Size And Forecast - 2023-2031 | Cipla Ltd., GlaxoSmithKline …
Newark, New Castle, USA - The latest report from Growth Plus Reports analyzes the production, potential applications, demand, major manufacturers, and SWOT analysis of the global Genital Warts Market.
The Genital Warts Market Report assists in determining the optimum distribution methods for certain products as well as possible markets for future product launches. The report also analyses the purchase and supply trends that influence the market's production strategy. The Genital Warts…
Investigation announced for Long-Term Investros in Verrica Pharmaceuticals Inc. …
An investigation was announced concerning potential breaches of fiduciary duties by certain directors and officers of Verrica Pharmaceuticals Inc..
Investors who are current long term investors in Verrica Pharmaceuticals Inc. (NASDAQ: VRCA) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in NASDAQ: VRCA stocks follows a lawsuit filed against Verrica…
Lawsuit filed for Investors in shares of Verrica Pharmaceuticals Inc. (NASDAQ: V …
An investor, who purchased shares of Verrica Pharmaceuticals Inc. (NASDAQ: VRCA), filed a lawsuit over alleged Securities Laws violations by Verrica Pharmaceuticals Inc. in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Verrica Pharmaceuticals Inc. (NASDAQ: VRCA) ou have certain options and for certain investors are short and strict deadlines running. Deadline: August 5, 2022. NASDAQ: VRCA investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or…
